NOLASIBAN


Synonyms	Erlosiban Nolasiban
Status
Molecule Category	UNKNOWN
UNII	3765U8A1EC


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	OLUJSZLBWZWGJT-HGBKYHTQSA-N
Smiles	CO/N=C1/C[C@@H](CO)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1
InChI	InChI=1S/C20H22N2O3/c1-14-5-3-4-6-19(14)15-7-9-16(10-8-15)20(24)22-12-17(21-25-2)11-18(22)13-23/h3-10,18,23H,11-13H2,1-2H3/b21-17-/t18-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H22N2O3
Molecular Weight	338.41
AlogP	2.87
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	62.13
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	25.0

Bioactivity

Mechanism of Action	Action	Reference
Oxytocin receptor antagonist	ANTAGONIST	PubMed


Protein: Oxytocin receptor Description: Oxytocin receptor Organism : Homo sapiens P30559 ENSG00000180914

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Vasopressin and oxytocin receptor	-	-	-	210	-

Assay Description	Organism	Bioactivity
Displacement of [3H]-oxytocin from human oxytocin receptor expressed in CHO cells	Homo sapiens	95.0 nM
Displacement of [3H]vasopressin from human vasopressin V1a receptor expressed in CHO cells	Homo sapiens	330.0 nM
Displacement of [3H]-oxytocin from rat oxytocin receptor expressed in CHO cells	Rattus norvegicus	210.0 nM
Inhibition of oxytocin-induced uterine contraction in non-pregnant rat at 30 mg/kg, po	Rattus norvegicus	51.0 %
Inhibition of oxytocin-induced uterine contraction in pregnant rat at 60 mg/kg, po	Rattus norvegicus	40.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL1254025
DrugBank	DB16259
FDA SRS	3765U8A1EC
PubChem	52947354
SureChEMBL	SCHEMBL16550711
ZINC	ZINC000064491763

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).